After ending the month of January sharply lower, U.S. stock market started its new month of February with gains, wavering off early losses impelled by statistics that represented slowing activity in the U.S. manufacturing sector.
Headlines:
Ardelyx Inc, (NASDAQ:ARDX), declined -30.58% and is now trading at $18.75, soon after the biotech company declared that AstraZeneca’s 161-patient Phase 2b clinical trial evaluating tenapanor in hyperphosphatemic patients with chronic kidney disease on hemodialysis met its primary endpoint by demonstrating a statistically noteworthydose-related decrease in serum phosphate levels for tenapanor-treated patients contrast to patients receiving placebo (p=0.012). It was noted, however, that the rate of diarrhea was distinctly higher than predictable. The overall safety profile remains constant with that observed in prior tenapanor trials. In October 2012, Ardelyx reached a partnership with AstraZeneca for the worldwide development and commercialization of tenapanor.
Ardelyx Inc. (ARDX), discovers, develops, and commercializes non-systemic small molecule therapeutics for the gastrointestinal tract to treat cardio-renal and metabolic diseases.
Following healthcare stocks are also declining during its recent trade, and their comprehensive data (along with news and profile) is described as under:
BG Medicine, Inc (NASDAQ:BGMD), dipped -12.26% and is now trading at $0.930,as a diagnostics company, declared recently its receipt of a favorable decision from the Listing Qualifications Department of The NASDAQ Stock Market LLC, which granted the Company’s request for kept on listing on NASDAQ, following an extension within which to evidence compliance with NASDAQ Listing Rule 5550(b). In the Company’s case, the Rule requires the Company to evidence either a minimum of $2.5 million in stockholders’ equity or a market capitalization of at least $35 million. The Company is diligently working to evidence compliance with the Rule on or before May 19, 2015, as required by the Staff.
BG Medicine, Inc (BGMD), a diagnostics company develops and commercializes novel cardiovascular diagnostic tests to address unmet medical needs in the United States.
Venaxis Inc. (NASDAQ:APPY), dropped -6.44% and is now trading at $0.468. The stock was trading on a volume of 646,139.00 shares and the average volume of the stock remained 628,685.00 shares.
Venaxis Inc (APPY), develops and commercializes products for unmet diagnostic and therapeutic needs. The company’s research and development activities primarily focus on a human acute appendicitis blood-based test.
Synta Pharmaceuticals Corp (NASDAQ:SNTA), plunged -4.62% and is now trading at $2.28 around 535,535.00 shares have changed hands in this session. After opening at $2.39, the stock hit as high as $2.42. However, it traded between $2.18 and $7.22 over the last twelve months.
Synta Pharmaceuticals Corp. (SNTA), a biopharmaceutical organization focuses on the discovery, development, and commercialization of small molecule drugs for treating severe medical conditions, counting cancer and chronic inflammatory diseases.
Spark Therapeutics, Inc (NASDAQ:ONCE), decreased -6.10% and is now trading at $46.95, the company recently declared the pricing of its initial public offering of 7,000,000 shares of ordinary stock at a public offering price of $23.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Spark. In addition, Spark has granted the underwriters an option to purchase up to 1,050,000 additional shares of ordinary stock at the public offering price, less the underwriting discount.
Spark Therapeutics Inc (ONCE), is engaged in the field of gene therapy. The organization develops one-time, life-altering treatments for patients suffering from debilitating genetic diseases. The Company is focused on treating rare diseases where no, or only palliative therapies exist.
